SMAIO SA
PAR:ALSMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (23.5), the stock would be worth €-7.71 (203% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -22.8 | €7.48 |
0%
|
| Industry Average | 23.5 | €-7.71 |
-203%
|
| Country Average | 15.5 | €-5.09 |
-168%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
€37.5m
|
/ |
Jul 2025
€-1.9m
|
= |
|
|
€37.5m
|
/ |
Dec 2025
€-1.6m
|
= |
|
|
€37.5m
|
/ |
Dec 2026
€317.2k
|
= |
|
|
€37.5m
|
/ |
Dec 2027
€1.7m
|
= |
|
|
€37.5m
|
/ |
Dec 2028
€5.8m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| FR |
S
|
SMAIO SA
PAR:ALSMA
|
42.2m EUR | -22.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 58 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 43.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 21.3 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 11 |
| Median | 15.5 |
| 70th Percentile | 26.8 |
| Max | 3 102.9 |
Other Multiples
SMAIO SA
Glance View
S.M.A.I.O SA engages in the design, manufacture, and distribution of medical devices for the treatment of spinal pathologies. The company is headquartered in Saint-Priest, Auvergne-Rhone-Alpes and currently employs 30 full-time employees. The company went IPO on 2022-04-06. The firm provides control on a surgical procedure to spine physician through a wide range of solutions like surgical plan/ i-plan, surgical procedure i-perform, outcome data/ i-check, and education/ i-learn. The company operates with the clinical data and imaging for specialists in spine surgery for transformation of the vertebral fusion. The company also offers spine surgeons a complete solution, consisting of software, implantable devices, associated services, and treat spinal pathologies requiring surgery. The company includes Kheiron Spinal Fixation System, a device that incorporates many implants, intended for the immobilization and stabilization of spinal segments as an adjunct to fusion of the thoracic, lumbar and/or sacral spine. The company also develops the Keops and Balance Analyzer 3D surgical planning and patient database management software,
